Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other 1

Conditions

Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma 19Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 14Neoplasms, Plasma Cell 12Leukemia 12Neuroblastoma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large B-Cell, Diffuse 9Hodgkin Disease 9Recurrence 7Melanoma 7Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Burkitt Lymphoma 7Sarcoma 6Ovarian Neoplasms 6Myeloproliferative Disorders 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Sarcoma, Ewing 5Neoplasm Metastasis 5Medulloblastoma 5Lymphoma, B-Cell, Marginal Zone 5Liver Neoplasms 5Wilms Tumor 4Rhabdomyosarcoma 4Retinoblastoma 4

Interventions

Amifostine 4Filgrastim 3Cyclophosphamide 3Melphalan 2Irinotecan 2Cytarabine 2Carboplatin 2spartalizumab 1sodium thiosulfate 1sargramostim 1lometrexol 1etoposide phosphate 1Vincristine 1Temozolomide 1Sirolimus 1Procarbazine 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Mannitol 1Lomustine 1Interleukin-2 1Idarubicin 1Genetic Therapy 1Gemcitabine 1Folic Acid 1Fibroblast Growth Factor 7 1Fecal Microbiota Transplantation 1Drug Therapy 1Deoxycytidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Drug-Related Side Effects and Adverse Reactions × Melphalan × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡